Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Other Accumulated Expenses (2024 - 2025)

Coeptis Therapeutics Holdings (COEP) has 2 years of Other Accumulated Expenses data on record, last reported at $120000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses changed N/A year-over-year to $120000.0; the TTM value through Sep 2025 reached $120000.0, changed N/A, while the annual FY2024 figure was $235000.0, N/A changed from the prior year.
  • Other Accumulated Expenses reached $120000.0 in Q3 2025 per COEP's latest filing, down from $235000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $235000.0 in Q4 2024 and bottomed at $120000.0 in Q3 2025.